The identification of CCR7 as intermediate of CAD development is not surprising since this chemokine receptor together with its ligands CCL19 and CCL21 conforms an axis that has been characterized as a regulator of the maturation and migration of T-lymphocytes and lymphoid tumor cells (see [36,37] for reviews), and CAD has a deep inflammatory component [38]. This evidence concerns the gene CCR7 and lymphoid neoplasm.